Wipfli Financial Advisors’s Atara Biotherapeutics ATRA Stock Holding History

Wipfli Financial Advisors’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$12K	Buy	+123	New	+$13.8K	﹤0.01%	1769

Other funds holding ATRA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wipfli Financial Advisors's ATRA Position: Q3 2022 in Review

Wipfli Financial Advisors opened a new position in Atara Biotherapeutics (ATRA) in Q3 2022: 123 shares worth $12K. The stake represents ﹤0.01% of the portfolio and ranks #1769 among its holdings.

154 funds tracked by Wall St. Rank hold ATRA as of Q3 2022.

Wipfli Financial Advisors held 123 shares of Atara Biotherapeutics worth $12K as of Q3 2022.
Atara Biotherapeutics was a new Wipfli Financial Advisors position in Q3 2022.
Atara Biotherapeutics made up ﹤0.01% of Wipfli Financial Advisors's portfolio in Q3 2022, its #1769 holding.
154 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q3 2022.

Based on Wipfli Financial Advisors's 13F filing for Q3 2022, filed 26 Oct 2022.